Breast cancer in situ, also called ductal carcinoma in situ or DCIS, is the earliest form of breast cancer where abnormal cells are found in the milk ducts but have not spread beyond them. Understanding your treatment options—from surgery to radiation to hormone therapy—can help you feel more confident in making decisions that are right for your situation and your life.

Catching Cancer at Its Earliest Stage

When someone receives a diagnosis of breast cancer in situ, it means that abnormal cells have been found inside the milk ducts of the breast, but these cells have not yet broken through the duct walls into the surrounding breast tissue. This condition is most commonly known as ductal carcinoma in situ, often shortened to DCIS. The term “in situ” is a medical phrase meaning “in place,” which tells us that the abnormal cells remain exactly where they started and have not invaded nearby tissue.^[1]

DCIS is sometimes called stage 0 breast cancer, noninvasive breast cancer, or pre-invasive breast cancer. These names reflect the fact that the cancer cells are contained within the milk ducts and have not spread to other parts of the breast or body. While DCIS itself is not life-threatening, it does require attention and treatment because, if left untreated, some cases could eventually develop into invasive breast cancer—a more serious condition where cancer cells break out of the ducts and spread into surrounding breast tissue.^[2]

The diagnosis of DCIS has become much more common in recent decades, not because more people are developing it, but because screening mammograms detect it more often. Before routine mammography became widespread, DCIS made up less than 5% of breast cancer diagnoses. Today, it accounts for about 20% to 25% of all breast cancer cases diagnosed in the United States, with approximately 59,080 new cases expected in women each year. The condition can occur in men too, but this is extremely rare, representing less than 0.1% of cancer diagnoses.^[5][6]

Standard Treatment Approaches for Breast Cancer In Situ

The main goal of treating DCIS is to prevent it from developing into invasive breast cancer. Because doctors cannot currently predict which cases of DCIS will progress to invasive cancer and which will not, almost all cases are treated. Without treatment, studies suggest that anywhere from 10% to 50% of DCIS cases might progress to invasive breast cancer over time. The primary treatment for DCIS is surgery, and this is typically the first step recommended by healthcare providers.^[7][8]

Surgical Options

There are two main surgical approaches for treating DCIS. The first is called breast-conserving surgery, also known as a lumpectomy or wide local excision. During this procedure, the surgeon removes the area of DCIS along with a border of healthy tissue around it, called a margin. This surgery allows the person to keep most of their breast. The second option is mastectomy, which involves removing the entire breast. Your surgeon may recommend one particular surgery based on your specific situation, or they may give you a choice between the two procedures.^[2][10]

Several factors influence which surgery might be best for you. A mastectomy may be recommended if the area of DCIS is large, if there are multiple areas of DCIS in different parts of the breast, if the margins around the removed tissue show abnormal cells after lumpectomy, or if the DCIS is high grade with certain concerning features. Some people choose mastectomy even when lumpectomy is an option because removing the whole breast makes them feel more confident that all the abnormal cells have been taken out. Others prefer to keep as much of their breast as possible. Both choices are valid, and the decision should reflect what feels right for your situation and priorities.^[2]

Radiation Therapy After Surgery

If you have breast-conserving surgery, your doctor may recommend radiation therapy to treat the rest of the breast tissue. This treatment typically lasts three to four weeks and aims to destroy any abnormal cells that might still be present in the breast after surgery. Radiation therapy is particularly recommended if the DCIS cells look very abnormal under the microscope, which doctors describe as high grade. The purpose of radiation is to reduce the risk of DCIS coming back in the same breast.^[7][10]

Clinical trials from 15 to 20 years ago showed that adding radiation therapy after lumpectomy reduced the risk of DCIS recurrence by about half. However, it’s important to understand that radiation treatment does not change survival rates. The 10-year survival rate for women diagnosed with DCIS is 98% regardless of whether they receive radiation therapy. This means radiation is about reducing the risk of cancer returning to the breast rather than extending life. Your doctor or breast care nurse should discuss with you the potential benefits and risks of radiation therapy so you can make an informed decision.^[13]

Radiation therapy can cause side effects, which vary from person to person. Common side effects include skin changes in the treated area, similar to sunburn, as well as fatigue. These effects are usually temporary and improve after treatment ends. Your radiation oncology team will help manage any side effects that occur during and after treatment.

Hormone Therapy

After surgery and radiation, some people may be offered hormone therapy, also called endocrine therapy. This treatment is used when DCIS cells have receptors for hormones like estrogen or progesterone. Hormone therapy works by blocking the effects of these hormones or lowering their levels in the body, which can help prevent DCIS from coming back and reduce the risk of developing a new breast cancer.

Hormone therapy for DCIS typically involves taking a pill once a day for five years. The most commonly used medications are tamoxifen and aromatase inhibitors. Clinical trials have shown that hormone therapy can reduce the risk of recurrence by about a quarter when added to surgery and radiation. However, like radiation, hormone therapy does not improve survival rates for DCIS.^[13]

A recent study from Columbia University examined whether the benefits of hormone therapy outweigh its side effects for most people with DCIS. The researchers found that in many cases, the side effects of hormone therapy—which can include hot flashes, joint pain, mood changes, and increased risk of blood clots or bone loss—may outweigh the small reduction in recurrence risk. This is especially true when hormone therapy is added after both surgery and radiation. The decision about whether to take hormone therapy should involve a careful discussion with your doctor about your individual risk factors, the specific features of your DCIS, and how the potential side effects might affect your quality of life.^[13]

Research and Clinical Trials: Exploring New Approaches

Because DCIS treatment has traditionally followed approaches used for invasive breast cancer, researchers are now questioning whether all people with DCIS need the same level of treatment. There is growing concern that DCIS may be overtreated in some cases, particularly when the benefits of treatment after surgery are small but the impact on quality of life is significant. This has led to several important research efforts aimed at understanding DCIS better and finding the optimal treatment for different situations.^[13]

Active Surveillance Studies

One of the most significant areas of research involves studying whether some people with low-risk DCIS could be safely monitored with regular mammograms and check-ups instead of immediately having surgery. This approach is called active surveillance. Several clinical trials have been established to carefully monitor patients with DCIS rather than treating them with surgery right away. These studies aim to provide more precise information about what percentage of DCIS cases actually progress to invasive cancer and how long this progression takes.^[8]

A recent study funded by the National Cancer Institute used mathematical models to estimate the natural history of DCIS. The researchers found that between 36% and 100% of DCIS cases might progress to invasive breast cancer if left untreated, with an average progression time ranging from 0.2 to 2.5 years. However, these wide ranges reflect the uncertainty and variation in DCIS behavior. Some DCIS cases are likely to remain stable and never cause harm, while others may progress more quickly. The challenge is that doctors cannot yet tell which cases will do which.^[8]

Understanding Risk Factors

Researchers are also working to identify which factors make DCIS more likely to progress. Studies have shown that high-grade DCIS—where cells look very abnormal under the microscope—is more likely to come back after treatment and more likely to spread into surrounding breast tissue and become invasive cancer. Certain genetic mutations, particularly in the BRCA1 and BRCA2 genes, may also increase risk. Understanding these risk factors better will help doctors tailor treatment recommendations to each person’s specific situation.^[2][8]

Improving Diagnostic Tools

Another important area of research involves developing better diagnostic tools to predict which DCIS cases are more likely to become invasive. Scientists are studying the molecular and genetic characteristics of DCIS cells to identify markers that indicate higher risk. This research includes analyzing specific gene patterns, protein expressions, and other biological features of the cancer cells. The goal is to create tests that can guide more personalized treatment decisions, ensuring that people receive the level of treatment appropriate for their specific risk level.

Testing Modified Treatment Approaches

Clinical trials are also testing modified treatment approaches for DCIS. Some studies are exploring whether shorter courses of radiation therapy might be as effective as the standard three to four weeks while causing fewer side effects. Other trials are investigating whether radiation can be safely omitted for certain low-risk cases of DCIS after lumpectomy. These studies carefully track outcomes to ensure that any reduction in treatment intensity does not lead to worse results for patients.

Researchers are also examining the optimal duration and type of hormone therapy for DCIS. While the standard recommendation has been five years of treatment, studies are investigating whether shorter durations might provide similar benefits with fewer side effects for certain groups of patients. This research is particularly important given recent findings suggesting that the benefits of hormone therapy may not always outweigh the side effects for people with DCIS.

Making Treatment Decisions

Deciding on treatment for DCIS can feel overwhelming, especially since the condition itself is not immediately life-threatening. Unlike invasive cancer where treatment urgency is clear, DCIS allows some time to gather information and consider your options carefully. It’s important to have open conversations with your healthcare team about what matters most to you and how different treatment options might affect your life.

When discussing treatment options, consider asking your doctor about the grade of your DCIS (low, intermediate, or high), the size of the affected area, whether there are multiple areas of DCIS in your breast, and what your specific risk of recurrence or progression might be. Understanding these details can help you weigh the benefits and potential downsides of different treatments. Many people find it helpful to bring a family member or friend to appointments to help listen and take notes, as it can be difficult to absorb all the information when you’re feeling stressed or anxious.^[10]

Getting a second opinion is completely appropriate and can give you greater confidence in your treatment plan. Speaking with another specialist may provide new perspectives or alternative treatment options that work better for your lifestyle and priorities. Most doctors understand and support patients seeking additional input on important health decisions.

Most Common Treatment Methods

• Breast-Conserving Surgery (Lumpectomy or Wide Local Excision)
  • Removes the area of DCIS and a border of healthy tissue around it
  • Allows most of the breast to be preserved
  • Often followed by radiation therapy to reduce recurrence risk
  • May be repeated if margins show abnormal cells
• Mastectomy
  • Removes the entire breast
  • Recommended when DCIS area is large or there are multiple areas in different parts of the breast
  • May be chosen by patient preference for peace of mind
  • Breast reconstruction is an option that can be done at the same time or later
• Radiation Therapy
  • Typically given after breast-conserving surgery
  • Usually lasts three to four weeks
  • Reduces risk of DCIS returning by about half
  • Particularly recommended for high-grade DCIS
  • Common side effects include skin changes and fatigue
• Hormone Therapy (Endocrine Therapy)
  • Used when DCIS cells have hormone receptors
  • Includes medications like tamoxifen or aromatase inhibitors
  • Taken as a daily pill for five years
  • Reduces recurrence risk by about a quarter
  • Side effects may include hot flashes, joint pain, and mood changes